Anne Wojcicki Keynote Speaker

Pioneer in healthcare and geonomics
Co-founder and CEO, 23andMe (2006-2025)
10-year background in healthcare investing

Anne Wojcicki's Biography

Anne Wojcicki is an innovative biologist and the Co-founder and Chief Executive Officer (2006-2025) of the personal genomics company 23andMe. 23andMe provides rapid genetic testing for individuals curious about their ancestry and genetic make-up, and is a platform for researchers looking for study participants. It has one of the world’s largest databases of individual genetic information.

From her vantage point, Anne saw a need for creating a way to generate more information – especially more personalised information – so that commercial and academic researchers could better understand and develop new drugs and diagnostics. Anne brings to 23andMe a 10-year background in healthcare investing, focusing on biotechnology companies. Disillusioned by the culture of Wall Street and its attitude towards health care, Anne left the investing world with the hope that she could have a positive impact on research and medicine through 23andMe.

The company’s novel, web-based research approach allows for the rapid recruitment of participants to many genome-wide association studies at once, reducing the time and money needed to make new discoveries. 23andMe’s personal genome test kit was named Invention of the Year by Time magazine in 2008, and in 2013, The Fast Company named Anne as “The Most Daring CEO”.

She co-founded and led 23andMe to build one of the world’s largest personal genomics databases, transforming how individuals access and understand their own genetic information.
She translates advances in biotechnology and data driven research into clear insights that help leaders grasp the commercial and ethical implications of personalised medicine.
She draws on a decade of healthcare investing experience to explain how capital, innovation and scientific discovery intersect to accelerate drug development and diagnostics.
She challenges organisations to rethink traditional research models, demonstrating how technology enabled platforms can reduce the time and cost required to bring breakthroughs to market.
Her experience disrupting both Wall Street convention and the healthcare industry equips audiences to lead boldly at the intersection of science, technology and societal impact.